In this Healio Video Perspective from the virtual ARVO meeting, Michael Singer, MD, discusses increase in IOP viewed as a “24-month snapshot” in the completer data of the PALADIN study.
The PALADIN study is an ongoing 3-year prospective phase 4 study looking at use of Iluvien (fluocinolone acetonide intravitreal implant 0.19 mg, Alimera Sciences) in patients with diabetic macular edema.